EssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression

Dow Jones

09/26

By Kelly Cloonan

EssilorLuxottica has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children.

The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally.

The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said.

Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life.

Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

September 25, 2025 18:05 ET (22:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2570404249"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570404249\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570404249?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570404249","market":"hk","top_or_hot":-1,"title":"EssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ESLOF\">EssilorLuxottica</a> has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children. \n</p>\n<p>\n  The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally. \n</p>\n<p>\n  The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said. \n</p>\n<p>\n  Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life. \n</p>\n<p>\n  Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 25, 2025 18:05 ET (22:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-26 06:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ESLOF\">EssilorLuxottica</a> has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children. \n</p>\n<p>\n  The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally. \n</p>\n<p>\n  The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said. \n</p>\n<p>\n  Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life. \n</p>\n<p>\n  Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 25, 2025 18:05 ET (22:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESLOY","symbol_name":"EssilorLuxottica","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2570404249","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570404249","pubTimestamp":1758837900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"EssilorLuxottica has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children.The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally.The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said.Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESLOY":"EssilorLuxottica","BK4198":"医疗保健用品","BK4202":"服装、服饰与奢侈品","06613":"蓝思科技","BK1170":"电子元件"},"translate_title":"EssilorLuxottica获得FDA批准用于减缓近视进展的镜片","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06613":1.5,"ESLOY":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\nEssilorLuxottica has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children. \n\n\n  The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally. \n\n\n  The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said. \n\n\n  Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life. \n\n\n  Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 25, 2025 18:05 ET (22:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}